{"id":"https://openalex.org/W1986314685","doi":"https://doi.org/10.1111/bcpt.12090","title":"Pharmacological Characterisation of a Structurally Novel \u03b12C \u2010Adrenoceptor Antagonist ORM \u201010921 and its Effects in Neuropsychiatric Models","display_name":"Pharmacological Characterisation of a Structurally Novel \u03b12C \u2010Adrenoceptor Antagonist ORM \u201010921 and its Effects in Neuropsychiatric Models","publication_year":2013,"publication_date":"2013-05-30","ids":{"openalex":"https://openalex.org/W1986314685","doi":"https://doi.org/10.1111/bcpt.12090","mag":"1986314685","pmid":"https://pubmed.ncbi.nlm.nih.gov/23718812"},"language":"en","primary_location":{"id":"doi:10.1111/bcpt.12090","doi":"https://doi.org/10.1111/bcpt.12090","is_oa":false,"landing_page_url":"https://doi.org/10.1111/bcpt.12090","pdf_url":null,"source":{"id":"https://openalex.org/S44074210","display_name":"Basic & Clinical Pharmacology & Toxicology","issn_l":"1742-7835","issn":["1742-7835","1742-7843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Basic & Clinical Pharmacology & Toxicology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5079206286","display_name":"Jukka Sallinen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210118237","display_name":"Orion Corporation (Finland)","ror":"https://ror.org/0296s4x19","country_code":"FI","type":"company","lineage":["https://openalex.org/I4210118237"]}],"countries":["FI"],"is_corresponding":true,"raw_author_name":"Jukka Sallinen","raw_affiliation_strings":["Orion Corporation Orion Pharma, Research and Development, Turku, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orion Corporation Orion Pharma, Research and Development, Turku, Finland","institution_ids":["https://openalex.org/I4210118237"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088014992","display_name":"Johanna Holappa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210118237","display_name":"Orion Corporation (Finland)","ror":"https://ror.org/0296s4x19","country_code":"FI","type":"company","lineage":["https://openalex.org/I4210118237"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Johanna Holappa","raw_affiliation_strings":["Orion Corporation Orion Pharma, Research and Development, Turku, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orion Corporation Orion Pharma, Research and Development, Turku, Finland","institution_ids":["https://openalex.org/I4210118237"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073685415","display_name":"Ari Koivisto","orcid":"https://orcid.org/0000-0003-1389-9521","observed_orcids":["https://orcid.org/0000-0003-1389-9521"]},"institutions":[{"id":"https://openalex.org/I4210118237","display_name":"Orion Corporation (Finland)","ror":"https://ror.org/0296s4x19","country_code":"FI","type":"company","lineage":["https://openalex.org/I4210118237"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Ari Koivisto","raw_affiliation_strings":["Orion Corporation Orion Pharma, Research and Development, Turku, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orion Corporation Orion Pharma, Research and Development, Turku, Finland","institution_ids":["https://openalex.org/I4210118237"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089107785","display_name":"Katja Kuokkanen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210118237","display_name":"Orion Corporation (Finland)","ror":"https://ror.org/0296s4x19","country_code":"FI","type":"company","lineage":["https://openalex.org/I4210118237"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Katja Kuokkanen","raw_affiliation_strings":["Orion Corporation Orion Pharma, Research and Development, Turku, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orion Corporation Orion Pharma, Research and Development, Turku, Finland","institution_ids":["https://openalex.org/I4210118237"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045973712","display_name":"Hugh Chapman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210118237","display_name":"Orion Corporation (Finland)","ror":"https://ror.org/0296s4x19","country_code":"FI","type":"company","lineage":["https://openalex.org/I4210118237"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Hugh Chapman","raw_affiliation_strings":["Orion Corporation Orion Pharma, Research and Development, Turku, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orion Corporation Orion Pharma, Research and Development, Turku, Finland","institution_ids":["https://openalex.org/I4210118237"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103241244","display_name":"Jyrki Lehtim\u00e4ki","orcid":"https://orcid.org/0000-0002-0094-8251","observed_orcids":["https://orcid.org/0000-0002-0094-8251"]},"institutions":[{"id":"https://openalex.org/I4210118237","display_name":"Orion Corporation (Finland)","ror":"https://ror.org/0296s4x19","country_code":"FI","type":"company","lineage":["https://openalex.org/I4210118237"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Jyrki Lehtim\u00e4ki","raw_affiliation_strings":["Orion Corporation Orion Pharma, Research and Development, Turku, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orion Corporation Orion Pharma, Research and Development, Turku, Finland","institution_ids":["https://openalex.org/I4210118237"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5002752890","display_name":"Petteri T. Piepponen","orcid":"https://orcid.org/0000-0002-2318-1612","observed_orcids":["https://orcid.org/0000-0002-2318-1612"]},"institutions":[{"id":"https://openalex.org/I133731052","display_name":"University of Helsinki","ror":"https://ror.org/040af2s02","country_code":"FI","type":"education","lineage":["https://openalex.org/I133731052"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Petteri Piepponen","raw_affiliation_strings":["Division of Pharmacology and Toxicology, University of Helsinki, Helsinki, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacology and Toxicology, University of Helsinki, Helsinki, Finland","institution_ids":["https://openalex.org/I133731052"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109540492","display_name":"Jelena Mijatovic","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I133731052","display_name":"University of Helsinki","ror":"https://ror.org/040af2s02","country_code":"FI","type":"education","lineage":["https://openalex.org/I133731052"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Jelena Mijatovic","raw_affiliation_strings":["Division of Pharmacology and Toxicology, University of Helsinki, Helsinki, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Pharmacology and Toxicology, University of Helsinki, Helsinki, Finland","institution_ids":["https://openalex.org/I133731052"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005270668","display_name":"Heikki Tanila","orcid":"https://orcid.org/0000-0001-8579-7562","observed_orcids":["https://orcid.org/0000-0001-8579-7562"]},"institutions":[{"id":"https://openalex.org/I175532246","display_name":"University of Eastern Finland","ror":"https://ror.org/00cyydd11","country_code":"FI","type":"education","lineage":["https://openalex.org/I175532246"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Heikki Tanila","raw_affiliation_strings":["Department of Neurobiology; A. I. Virtanen Institute; University of Eastern Finland and CNServices Ltd; Kuopio; Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurobiology; A. I. Virtanen Institute; University of Eastern Finland and CNServices Ltd; Kuopio; Finland","institution_ids":["https://openalex.org/I175532246"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111655171","display_name":"Raimo Virtanen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210118237","display_name":"Orion Corporation (Finland)","ror":"https://ror.org/0296s4x19","country_code":"FI","type":"company","lineage":["https://openalex.org/I4210118237"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Raimo Virtanen","raw_affiliation_strings":["Orion Corporation Orion Pharma, Research and Development, Turku, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orion Corporation Orion Pharma, Research and Development, Turku, Finland","institution_ids":["https://openalex.org/I4210118237"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111392906","display_name":"Jouni Sirvi\u00f6","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jouni Sirvi\u00f6","raw_affiliation_strings":["Department of Neurobiology, Sauloner Ltd., Kuopio, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurobiology, Sauloner Ltd., Kuopio, Finland","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5027596381","display_name":"Antti Haapalinna","orcid":"https://orcid.org/0000-0002-1179-6898","observed_orcids":["https://orcid.org/0000-0002-1179-6898"]},"institutions":[{"id":"https://openalex.org/I4210118237","display_name":"Orion Corporation (Finland)","ror":"https://ror.org/0296s4x19","country_code":"FI","type":"company","lineage":["https://openalex.org/I4210118237"]}],"countries":["FI"],"is_corresponding":false,"raw_author_name":"Antti Haapalinna","raw_affiliation_strings":["Orion Corporation Orion Pharma, Research and Development, Turku, Finland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orion Corporation Orion Pharma, Research and Development, Turku, Finland","institution_ids":["https://openalex.org/I4210118237"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5079206286"],"corresponding_institution_ids":["https://openalex.org/I4210118237"],"apc_list":{"value":4650,"currency":"USD","value_usd":4650},"apc_paid":null,"fwci":1.8058,"has_fulltext":false,"cited_by_count":44,"citation_normalized_percentile":{"value":0.81971376,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"113","issue":"4","first_page":"239","last_page":"249"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.5303000211715698,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10056","display_name":"Neurotransmitter Receptor Influence on Behavior","score":0.5303000211715698,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.3059000074863434,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11178","display_name":"Receptor Mechanisms and Signaling","score":0.08190000057220459,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alpha2a-adrenoceptor","display_name":"alpha2A-adrenoceptor","score":0.7870000004768372},{"id":"https://openalex.org/keywords/receptor-binding-affinity","display_name":"receptor binding affinity","score":0.527999997138977},{"id":"https://openalex.org/keywords/antidepressant-like-effects","display_name":"antidepressant-like effects","score":0.7919999957084656},{"id":"https://openalex.org/keywords/antipsychotic-like-effects","display_name":"antipsychotic-like effects","score":0.9919999837875366},{"id":"https://openalex.org/keywords/prepulse-inhibition","display_name":"prepulse inhibition","score":0.9929999709129333},{"id":"https://openalex.org/keywords/mk-801","display_name":"MK-801","score":0.9599999785423279},{"id":"https://openalex.org/keywords/nmda-receptor-antagonism","display_name":"NMDA receptor antagonism","score":0.8109999895095825},{"id":"https://openalex.org/keywords/social-behavior","display_name":"social behavior","score":0.718999981880188},{"id":"https://openalex.org/keywords/cognitive-impairment","display_name":"cognitive impairment","score":0.6510000228881836},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.9089999794960022},{"id":"https://openalex.org/keywords/alzheimer-s-disease","display_name":"Alzheimer's disease","score":0.9660000205039978}],"concepts":[{"id":"https://openalex.org/C2778851735","wikidata":"https://www.wikidata.org/wiki/Q407324","display_name":"Phencyclidine","level":4,"score":0.7898805141448975},{"id":"https://openalex.org/C50156730","wikidata":"https://www.wikidata.org/wiki/Q3856966","display_name":"Microdialysis","level":3,"score":0.7740175724029541},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.7709529995918274},{"id":"https://openalex.org/C2777383412","wikidata":"https://www.wikidata.org/wiki/Q4770891","display_name":"Antagonism","level":3,"score":0.7568005323410034},{"id":"https://openalex.org/C141421786","wikidata":"https://www.wikidata.org/wiki/Q1128897","display_name":"Prepulse inhibition","level":3,"score":0.7262259721755981},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6562466025352478},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.5852328538894653},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5314898490905762},{"id":"https://openalex.org/C67018056","wikidata":"https://www.wikidata.org/wiki/Q414896","display_name":"NMDA receptor","level":3,"score":0.49238836765289307},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.4780046045780182},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.4731011390686035},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.38591739535331726},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3528156280517578},{"id":"https://openalex.org/C28406088","wikidata":"https://www.wikidata.org/wiki/Q5571762","display_name":"Extracellular","level":2,"score":0.30360716581344604},{"id":"https://openalex.org/C15744967","wikidata":"https://www.wikidata.org/wiki/Q9418","display_name":"Psychology","level":0,"score":0.2303968369960785},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.20965498685836792},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.1297008991241455},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.10349279642105103},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000166","descriptor_name":"Acridines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000928","descriptor_name":"Antidepressive Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D001572","descriptor_name":"Benzofurans","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D002490","descriptor_name":"Central Nervous System","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D002490","descriptor_name":"Central Nervous System","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D002493","descriptor_name":"Central Nervous System Diseases","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D002493","descriptor_name":"Central Nervous System Diseases","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D004298","descriptor_name":"Dopamine","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007035","descriptor_name":"Hypothermia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":false},{"descriptor_ui":"D007035","descriptor_name":"Hypothermia","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010622","descriptor_name":"Phencyclidine","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D016291","descriptor_name":"Dizocilpine Maleate","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D017208","descriptor_name":"Rats, Wistar","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018341","descriptor_name":"Receptors, Adrenergic, alpha-2","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D018341","descriptor_name":"Receptors, Adrenergic, alpha-2","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D018696","descriptor_name":"Neuroprotective Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D054837","descriptor_name":"Quinolizidines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D058669","descriptor_name":"Adrenergic alpha-2 Receptor Antagonists","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1111/bcpt.12090","doi":"https://doi.org/10.1111/bcpt.12090","is_oa":false,"landing_page_url":"https://doi.org/10.1111/bcpt.12090","pdf_url":null,"source":{"id":"https://openalex.org/S44074210","display_name":"Basic & Clinical Pharmacology & Toxicology","issn_l":"1742-7835","issn":["1742-7835","1742-7843"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Basic & Clinical Pharmacology & Toxicology","raw_type":"journal-article"},{"id":"pmid:23718812","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/23718812","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Basic & clinical pharmacology & toxicology","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9391000270843506}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":46,"referenced_works":["https://openalex.org/W80296927","https://openalex.org/W81146768","https://openalex.org/W1479796757","https://openalex.org/W1480852888","https://openalex.org/W1505073877","https://openalex.org/W1528722660","https://openalex.org/W1529941862","https://openalex.org/W1975627286","https://openalex.org/W1979420282","https://openalex.org/W1984280194","https://openalex.org/W1997220582","https://openalex.org/W1997347471","https://openalex.org/W1998319866","https://openalex.org/W1998441599","https://openalex.org/W2003996864","https://openalex.org/W2021890797","https://openalex.org/W2022097360","https://openalex.org/W2023358654","https://openalex.org/W2023577040","https://openalex.org/W2025386813","https://openalex.org/W2032193303","https://openalex.org/W2039641058","https://openalex.org/W2043292527","https://openalex.org/W2043679010","https://openalex.org/W2049428499","https://openalex.org/W2054065376","https://openalex.org/W2055511334","https://openalex.org/W2057430839","https://openalex.org/W2057625606","https://openalex.org/W2064863480","https://openalex.org/W2065797163","https://openalex.org/W2086687352","https://openalex.org/W2087809804","https://openalex.org/W2087828327","https://openalex.org/W2089299823","https://openalex.org/W2090404564","https://openalex.org/W2091239274","https://openalex.org/W2092798664","https://openalex.org/W2111281708","https://openalex.org/W2140156016","https://openalex.org/W2141027531","https://openalex.org/W2141717754","https://openalex.org/W2333357828","https://openalex.org/W2474292363","https://openalex.org/W4296759713","https://openalex.org/W4406057327"],"related_works":["https://openalex.org/W4377094002","https://openalex.org/W2741165379","https://openalex.org/W2527637278","https://openalex.org/W4312720203","https://openalex.org/W2468144236","https://openalex.org/W2924676648","https://openalex.org/W1529941862","https://openalex.org/W2057625606","https://openalex.org/W2025386813","https://openalex.org/W2027285763"],"abstract_inverted_index":{"The":[0,94,113,129],"\u03b12-adrenoceptors":[1],"(ARs)":[2],"are":[3],"important":[4],"modulators":[5],"of":[6,10,36,52,97,241],"a":[7,15,37,140,224],"wide":[8],"array":[9],"physiological":[11],"responses.":[12],"As":[13],"only":[14,139],"few":[16],"selective":[17],"compounds":[18],"for":[19,67,102],"the":[20,33,64,110,144,160,164,175,184,203,218,239],"three":[21],"\u03b12-AR":[22],"subtypes":[23],"(\u03b12A":[24],",":[25],"\u03b12B":[26],"and":[27,50,54,79,120,171,179,209,215,237],"\u03b12C":[28,221],")":[29],"have":[30],"been":[31],"available,":[32],"pharmacological":[34],"profile":[35],"new":[38,196],"\u03b12C-selective":[39,191],"AR":[40,192],"antagonist":[41,193],"ORM-10921":[42,68,103,148,167,201],"is":[43,223],"reported.":[44],"Standard":[45],"in":[46,58,72,98,127,130,156,159,174,206,228],"vitro":[47,99],"receptor":[48],"assays":[49],"antagonism":[51,101],"\u03b12,":[53],"\u03b11-AR":[55],"agonist-evoked":[56],"responses":[57],"vivo":[59,131],"were":[60,124],"used":[61],"to":[62,77,117,151,243],"demonstrate":[63],"\u03b12C-AR":[65,100],"selectivity":[66,114],"which":[69],"was":[70,149],"tested":[71],"established":[73],"behavioural":[74,165],"models":[75,181],"related":[76],"schizophrenia":[78,233],"cognitive":[80],"dysfunction":[81],"with":[82,138,183,188],"an":[83],"emphasis":[84],"on":[85,109],"pharmacologically":[86],"induced":[87],"hypoglutamatergic":[88],"state":[89],"by":[90],"phencyclidine":[91],"or":[92,234],"MK-801.":[93],"Kb":[95],"values":[96],"varied":[104],"between":[105],"0.078-1.2":[106],"nM":[107],"depending":[108],"applied":[111],"method.":[112],"ratios":[115],"compared":[116],"\u03b12A-AR":[118],"subtype":[119],"other":[121],"relevant":[122],"receptors":[123],"10-100":[125],"times":[126],"vitro.":[128],"experiments":[132],"supported":[133],"its":[134],"potent":[135,169],"\u03b12C-antagonism":[136,242],"combined":[137],"weak":[141],"\u03b12A-antagonism.":[142],"In":[143,163],"pharmacodynamic":[145],"microdialysis":[146],"study,":[147],"found":[150],"increase":[152],"extracellular":[153],"dopamine":[154],"levels":[155],"prefrontal":[157],"cortex":[158],"baseline":[161],"conditions.":[162],"tests,":[166],"displayed":[168],"antidepressant":[170],"antipsychotic-like":[172],"effects":[173],"forced":[176],"swimming":[177],"test":[178],"prepulse-inhibition":[180],"analogously":[182],"previously":[185],"reported":[186],"results":[187,197],"structurally":[189],"different":[190],"JP-1302.":[194],"Our":[195],"also":[198],"indicate":[199],"that":[200,220],"alleviated":[202],"NMDA-antagonist-induced":[204],"impairments":[205],"social":[207],"behaviour":[208],"watermaze":[210],"navigation.":[211],"This":[212],"study":[213],"extends":[214],"further":[216],"validates":[217],"concept":[219],"-AR":[222],"potential":[225,240],"therapeutic":[226],"target":[227],"CNS":[229],"disorders":[230],"such":[231,245],"as":[232],"Alzheimer's":[235],"disease":[236],"suggests":[238],"treat":[244],"disorders.":[246]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":7},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":5}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2016-06-24T00:00:00"}